Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

The purpose of this study is to observe the effectiveness and safety of the use of a low initial dose regime (iPTH/100) in chronic kidney disease patients with secondary hyperparathyroidism (PTH>300pg/mL) and that require dialysis at least 3 times per week.

Study Overview

• Status: Completed
• Conditions: Renal Insufficiency, Chronic; Hemodialysis; Secondary Hyperparathyroidism; Hypercalcemia; Parathyroid Hormone
• Intervention / Treatment: Drug: Zemplar (paricalcitol)

Detailed Description

The study will be carried out in three dialysis centers in Peru. Each patient enrolled in the study will be followed during a 6 month period from the time of inclusion. Study visits will occur at Baseline and at Weeks 4, 8, 12 and 24 during the study.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 4

Contacts and Locations

Study Locations

• Peru
  • Callao, Peru, CALLAO 2
    • Site Reference ID/Investigator# 21401
  • Lima, Peru, Lima-11
    • Site Reference ID/Investigator# 23857
  • Lima, Peru
    • Site Reference ID/Investigator# 10941

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients >=18 years old with secondary hyperparathyroidism (PTH>300pg/mL, measured in the last 2 weeks).
• Patients on hemodialysis who require starting therapy with IV paricalcitol (de novo).
• Patients attending 3 hemodialysis sessions per week.
• Patients signing the informed consent approved by the Ethics Committee. If any individual is not capable of giving his/her consent, it can be obtained from a next of kin or from his/her legal representative, according to local laws and regulations.
• The decision to initiate treatment is upon the investigator and the decision to treat patients with IV paricalcitol must not be based on the inclusion of the patient in the study or any other way. The decision to treat a patient with IV paricalcitol will be taken prior to asking the patient to participate in the study.

Exclusion Criteria:

• Patients with any concomitant clinical condition that, according to the investigator's opinion, might impede an adequate assessment of the treatment response.
• Patients with severe hyperparathyroidism (PTH>3000pg/mL).
• Patients with a serum calcium level greater or equal to 10.5mg/dL, phosphorus greater or equal to 6.5mg/dL, or those with Calcium X Phosphorus product 65 (measured at least 2 weeks before the study).
• Patients with neoplastic disease.
• Pregnant or lactating women.
• Known hypersensitivity and/or toxicity to vitamin D metabolites and/or to other ingredients of the product.
• Having participated in another study with an investigational product or device within the previous 30 days or having planned to participate in another study within the same period of time as the actual study.
• Use of vitamin D analogue during the last 3 months prior to the inclusion to this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Zemplar (paracalcitol)	Drug: Zemplar (paricalcitol); Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.; Other Names: Zemplar; ABT-358; paricalcitol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Percentage of Patients Reaching at Least a 30% Reduction in PTH and/or Values in Range 150-300 pg/mL	The percentage of participants who achieved at least a 30% reduction in intact parathyroid hormone (iPTH) and/or an iPTH value in the range of 150 to 300 picograms per milliliter (pg/mL) at any post-baseline visit during the study. An iPTH value of 150-300 pg/ml is the target range recommended by the NKF KDOQI (National Kidney Foundation Kidney Disease Outcomes Quality Initiative) for End Stage Renal Disease patients.	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Reach the First 30% Reduction in PTH and/or a Value Between 150-300pg/mL	Median time to achieve at least a 30% reduction in intact parathyroid hormone (iPTH) and/or an iPTH value in the range of 150-300 pg/mL.	24 Weeks
Number of Participants With Hypercalcemia (>10.5mg/dL), Hyperphosphatemia (>6.5mg/dL) and/or Elevations of the Ca X P Product (>65).	The number of participants with hypercalcemia (defined as at least one calcium value of more than 10.5 milligrams per deciliter [mg/dL]), hyperphosphatemia (phosphorus value of more than 6.5 mg/dL), and/or elevation of Calcium X Phosphorus product (value greater than 65) during the 24 week study.	24 Weeks

Collaborators and Investigators

• Sponsor: Abbott
• Investigators: Study Director: Oscar E Guerra, MD, Abbott

Study record dates

Study Major Dates

• Study Start: May 1, 2009
• Primary Completion (ACTUAL): September 1, 2010
• Study Completion (ACTUAL): September 1, 2010

Study Registration Dates

• First Submitted: April 29, 2009
• First Submitted That Met QC Criteria: April 30, 2009
• First Posted (ESTIMATE): May 1, 2009

Study Record Updates

• Last Update Posted (ESTIMATE): October 31, 2011
• Last Update Submitted That Met QC Criteria: September 22, 2011
• Last Verified: September 1, 2011

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Neoplasms; Kidney Diseases; Urologic Diseases; Endocrine System Diseases; Parathyroid Diseases; Neoplastic Processes; Calcium Metabolism Disorders; Water-Electrolyte Imbalance; Renal Insufficiency, Chronic; Hyperparathyroidism; Neoplasm Metastasis; Renal Insufficiency; Hyperparathyroidism, Secondary; Hypercalcemia; Physiological Effects of Drugs; Micronutrients; Vitamins; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Ergocalciferols
• Other Study ID Numbers: W10-677